BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Genta Incorporated (OTCBB: GNTA.OB) announced today that data from clinical trials of the Company's late-stage compounds, Genasense® (oblimersen sodium) Injection and tesetaxel, will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will be held from May 29- June 2, 2009 in Orlando, FL.
